Evidence map›Paper›PMID 32562921›Full record

ArticleClinical imaging2020

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome: Spectrum of imaging findings.

Anna K Paschall, Moozhan Nikpanah, Faraz Farhadi, Elizabeth C Jones, Paul G Wakim, Andrew J Dwyer, Rabindra Gautam, Maria J Merino, Ramaprasad Srinivasan, W Marston Linehan and 1 more

Abstract read
In one paragraph

Article in Clinical imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome.Journal of the Belgian Society of Radiology · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anna K PaschallNational Institutes of Health Clinical Center, Radiology and Imaging Sciences, 10 Center Drive, Bethesda, MD 20814, United States of America; Duke University Health System, School of Medicine, 8 Searle Center Dr., Durham, NC 27710, United States of America.
Moozhan NikpanahNational Institutes of Health Clinical Center, Radiology and Imaging Sciences, 10 Center Drive, Bethesda, MD 20814, United States of America.
Faraz FarhadiNational Institutes of Health Clinical Center, Radiology and Imaging Sciences, 10 Center Drive, Bethesda, MD 20814, United States of America.
Elizabeth C JonesNational Institutes of Health Clinical Center, Radiology and Imaging Sciences, 10 Center Drive, Bethesda, MD 20814, United States of America.
Paul G WakimNational Institutes of Health Clinical Center, Biostatistics and Clinical Epidemiology Service, 10 Center Drive, Bethesda, MD 20814, United States of America.
Andrew J DwyerNational Institutes of Health Clinical Center, Radiology and Imaging Sciences, 10 Center Drive, Bethesda, MD 20814, United States of America.
Rabindra GautamNational Institutes of Health, National Cancer Institute- Urologic Oncology Branch, 10 Center Drive, Bethesda, MD 20814, United States of America.
Maria J MerinoNational Institutes of Health, National Cancer Institute- Laboratory of Pathology, 10 Center Drive, Bethesda, MD 20814, United States of America.
Ramaprasad SrinivasanNational Institutes of Health, National Cancer Institute- Urologic Oncology Branch, 10 Center Drive, Bethesda, MD 20814, United States of America.
W Marston LinehanNational Institutes of Health, National Cancer Institute- Urologic Oncology Branch, 10 Center Drive, Bethesda, MD 20814, United States of America.
Ashkan A MalayeriNational Institutes of Health Clinical Center, Radiology and Imaging Sciences, 10 Center Drive, Bethesda, MD 20814, United States of America. Electronic address: ashkan.malayeri@nih.gov.

Funding

Molecular Therapeutics of Kidney Cancer: VHL Gene and Fumarate Hydratase GeneZIABC011038 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$29.8M
Molecular Therapeutics of Kidney Cancer: MET Gene and BHD GeneZIABC011043 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$20.9M
Clinical Studies of the Molecular Genetic Basis of Kidney CancerZIABC011028 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$17.9M
Clinical Nursing and Data Management CoreZIDBC011089 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$17.4M
Study of Hereditary Renal and Other Familial SyndromesZIABC010696 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MERINO, MARIA · 2009 to 2025
$4.5M
Translational Surgical PathologyZIESC000853 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI MERINO, MARIA · 2009 to 2025
$4.3M
Novel Approaches to Targeting Cancers Associated with VHL MutationsZIABC011920 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SRINIVASAN, RAMAPRASAD · 2019 to 2025
$4.1M
Immunotherapy of kidney cancer. Where do the T lymphocytes go in kidney cancer?ZIABC012016 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MERINO, MARIA · 2020 to 2025
$1.6M
Clinical Studies of the Molecular Genetic Basis of Kidney CancerZ01BC011028 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2008 to 2008
$1.4M
Intramural NIH HHS Z01 BC011028Intramural NIH HHS ZIA BC010696Intramural NIH HHS ZIA BC011920
6 · The paper itself

Abstract

purposeTo retrospectively investigate the radiological presentations of HLRCC-associated renal tumors to facilitate accurate lesion characterization and compare these presentations with simple cysts and characteristics of other subtypes of renal cell carcinoma (RCC) as reported in the literature.

methodsThe MRI and CT imaging characteristics of 39 pathologically confirmed lesions from 30 patients (20 male, 10 female) with HLRCC syndrome were evaluated by two radiologists. Patients had an average age at diagnosis of 43.8 ± 13.1 years. Lesion characteristics including laterality, homogeneity, diameter (cm), nodularity, septations, T1 and T2 signal intensity, enhancement, and restricted diffusion were recorded. Imaging characteristics of the lesions were further compared to characteristics of benign simple cysts surgically removed at the same time point.

resultsThe examined lesions had a mean diameter of 5.06 ± 3.80 cm, an average growth rate of 2.91 × 10

conclusionsOur analysis confirmed that while HLRCC-associated renal lesions demonstrate diversity in imaging presentations, the majority are unilateral and solitary, T2-hyperintense, heterogeneous with well-defined margins, and frequently demonstrate restricted diffusion and nodularity.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsLeiomyomatosisNeoplastic Syndromes, HereditaryAdultFemaleHumansMaleMiddle AgedRetrospective StudiesCTGenitourinaryHLRCCMRIPapillary RCCRCC

Identifiers

PMID32562921
PMCPMC8916163

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.